Complement, thrombotic microangiopathy and disseminated intravascular coagulation

Area of Science:

• Hematology
• Immunology
• Pathophysiology

Background:

• Disseminated intravascular coagulation (DIC) and thrombotic microangiopathies (TMA) share clinical features like thrombocytopenia, hemolytic anemia, and thrombosis.
• Both conditions often show evidence of complement system activation.
• Therapeutic complement inhibition is increasingly considered for these disorders.

Purpose of the Study:

• To review the current knowledge on complement activation in TMA and DIC.
• To discuss the potential benefits and risks of complement inhibition strategies.
• To highlight the need for standardized assessment in these patient populations.

Main Methods:

• Literature review of studies on complement activation in TMA and DIC.
• Analysis of clinical observations and molecular etiologies.
• Discussion of therapeutic approaches and research gaps.

Main Results:

• Complement inhibition is effective in atypical hemolytic uremic syndrome (aHUS), a type of TMA.
• The success in aHUS raises questions about whether it targets disease etiology or acts as a systemic treatment.
• Similarities in complement activation and clinical presentation exist between TMA and DIC, despite different underlying causes.

Conclusions:

• Careful consideration is required before widespread complement inhibition in DIC due to diverse etiologies.
• More research is essential to establish effective and safe complement inhibition strategies for both TMA and DIC.
• Standardized assessment of complement activation's consequences is crucial for patient management.